Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.
about
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsEmerging and Evolving Ovarian Cancer Animal ModelsAntitumor effect of nuclear factor-κB decoy transfer by mannose-modified bubble lipoplex into macrophages in mouse malignant ascites.The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenNatural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology.Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time.A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histologyTargeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention.Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancerAnoikis resistance is a critical feature of highly aggressive ovarian cancer cells.Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions.PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesCD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and MetastasisEfficient construct of a large and functional scFv yeast display library derived from the ascites B cells of ovarian cancer patients by three-fragment transformation-associated recombination.Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment.Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and OriginsDysregulation of mitotic machinery genes precedes genome instability during spontaneous pre-malignant transformation of mouse ovarian surface epithelial cells.Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.Preclinical activity of melflufen (J1) in ovarian cancer.Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune ResponseThrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.Recently identified drug resistance biomarkers in ovarian cancer.Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapyThe Unique Molecular and Cellular Microenvironment of Ovarian CancerNewly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites CarcinomaPGC1α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells.
P2860
Q26738643-EA2A96AD-F93D-4B9C-81F8-FE3C5FAC9316Q26776553-AB5726B3-9A15-4670-A8C3-44A65C8BAF1AQ26783909-65C9E04C-7F4B-489B-A36F-D5D9FD699B11Q30401492-CDF5E923-64C1-4A45-BF6F-5392DF252692Q33574500-ED15D423-C823-4B7A-B65C-6DD4FDECB1A0Q33628532-0FF2B9F6-68BC-49A1-AC66-8418DE1D7B83Q33754724-E644D60A-E3EB-495F-BA33-BC70FE7FF1D4Q33872622-F3F395A9-3C2F-448A-BAB8-DE2B8C702D2FQ34350732-761F1461-3B93-4AA1-8FBE-803CC0409852Q34387999-237B3F51-6ECC-4301-99C7-4AD12A9FE922Q34504817-20CB6B1F-9FA7-4E87-BB5A-8414BAFBFF82Q34968735-A01BF020-6529-4528-8176-D4C63508045BQ35064627-F3C65B16-0DB1-4B21-B907-AD8C288AAAD3Q35097243-242D10F6-461E-4903-A60F-1C715B98C71FQ35109273-4365C104-9D44-406C-9777-DEFD09A41F4EQ35142408-4FE7DD46-C350-44CE-8A08-9CE9F4330F2EQ35470322-97B517FE-3891-49A2-8303-326322D030B7Q35832582-00177441-89A2-4AD6-9138-5D5E909B8846Q35897306-89E2B56C-AACD-41B5-B256-7ED38C25CBC9Q35908928-F6FB03BD-3C05-40B5-B206-3635041EDAA0Q35955337-24D18D3C-FEDF-41D5-BBB1-9C79A7C4A06FQ36070842-28119911-3347-4F5D-96AB-EC07BD31258CQ36097633-E9DBD985-FD84-408C-8A67-ADB943F2C4F7Q36179026-44EE7DAC-7682-4FEB-AE02-4F1F16C669C7Q36180735-33683DFB-9CC3-4E39-B15D-623C5C9E59FCQ36797297-7F483F4B-086B-45A4-A2BE-8770E945DB53Q37137451-54B7CC57-E346-46F7-951A-9460031C2962Q37317439-ED7093F5-980C-4E33-98F7-AD20F439593DQ37641608-39064462-4B42-46C3-9ED2-4997AFC75B0EQ37644866-120CB567-86CB-4125-9CC2-870BD9FCA1C3Q37696280-19D163AC-6158-4383-9FF0-FA28C118E545Q37703042-3D0C8401-2F7B-439A-85A4-C046E883231EQ37709136-22106BB2-012B-4DE3-B7DB-2AEF5A081C9DQ37710558-2CB7771A-3B79-4251-9827-82C00EBAE532Q38741073-E6D45446-E126-4B87-BEBA-CD4B06D4ED85Q38767385-B80E485A-05B8-46CF-9801-18A19BBEE562Q39169603-7B2296BF-7DB8-4D86-8D21-05FE3E1F74ACQ41137180-4FA84A69-D1B3-43D4-B986-6DFF27CE6896Q41213052-C88B6B5E-F5D5-4A5D-B80F-83BE20124BCAQ41694212-B9BDDB5F-11E9-4F72-8E1C-683B76577C84
P2860
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Getting to know ovarian cancer ...... -based translational research.
@en
Getting to know ovarian cancer ...... -based translational research.
@nl
type
label
Getting to know ovarian cancer ...... -based translational research.
@en
Getting to know ovarian cancer ...... -based translational research.
@nl
prefLabel
Getting to know ovarian cancer ...... -based translational research.
@en
Getting to know ovarian cancer ...... -based translational research.
@nl
P2860
P356
P1476
Getting to know ovarian cancer ...... -based translational research.
@en
P2093
Kaye L Stenvers
Nuzhat Ahmed
P2860
P356
10.3389/FONC.2013.00256
P577
2013-09-25T00:00:00Z